PMID- 32903146
OWN - NLM
STAT- MEDLINE
DCOM- 20210603
LR  - 20210603
IS  - 1758-1133 (Electronic)
IS  - 0049-4755 (Linking)
VI  - 51
IP  - 2
DP  - 2021 Apr
TI  - Immune reconstitution inflammatory syndrome: a report of TB-IRIS after switching 
      from efavirenz to dolutegravir.
PG  - 216-218
LID - 10.1177/0049475520953704 [doi]
AB  - In 2016, the World Health Organization adopted dolutegravir (DTG)-based 
      antiretroviral therapy as an alternative first-line treatment of HIV after many 
      clinical trials showed that it was more effective, better tolerated and more 
      protective than efavirenz and boosted protease inhibitors against discontinuation 
      of treatment from adverse drug reactions. However, there was concern that DTG 
      would lead to increased rates of immune reconstitution inflammatory syndrome 
      (IRIS), especially in the setting of late presentation to care. Three cases at 
      the University Teaching Hospital in Lusaka, Zambia highlight this concern, 
      especially in persons living with HIV (PLWH), resulting in tuberculosis (TB) 
      co-infection.
FAU - Zimba, Stanley
AU  - Zimba S
AUID- ORCID: 0000-0001-6861-6416
AD  - Internal Medicine Consultant and Neurology Registrar, Department of Internal 
      Medicine, University Teaching Hospital, Lusaka, Zambia.
FAU - Mbewe, Nyuma
AU  - Mbewe N
AD  - Infectious Diseases Registrar, Department of Internal Medicine, University 
      Teaching Hospital, Lusaka, Zambia.
FAU - Chishimba, Lorraine
AU  - Chishimba L
AD  - Neurology Registrar, Department of Internal Medicine, University Teaching 
      Hospital, Lusaka, Zambia.
FAU - Chomba, Mashina
AU  - Chomba M
AD  - Neurology Registrar, Department of Internal Medicine, University Teaching 
      Hospital, Lusaka, Zambia.
FAU - Saylor, Deanna
AU  - Saylor D
AD  - Honorary Consultant, University Teaching Hospital, Lusaka, Zambia.
AD  - Assistant Professor of Neurology, Department of Neurology, Johns Hopkins 
      University School of Medicine, Baltimore, MD, USA.
LA  - eng
PT  - Journal Article
DEP - 20200909
PL  - England
TA  - Trop Doct
JT  - Tropical doctor
JID - 1301706
RN  - 0 (Alkynes)
RN  - 0 (Benzoxazines)
RN  - 0 (Cyclopropanes)
RN  - 0 (Heterocyclic Compounds, 3-Ring)
RN  - 0 (Oxazines)
RN  - 0 (Piperazines)
RN  - 0 (Pyridones)
RN  - DKO1W9H7M1 (dolutegravir)
RN  - JE6H2O27P8 (efavirenz)
SB  - IM
MH  - Adult
MH  - Alkynes/*therapeutic use
MH  - Benzoxazines/*therapeutic use
MH  - Coinfection
MH  - Cyclopropanes/*therapeutic use
MH  - Female
MH  - HIV Infections/*drug therapy/epidemiology
MH  - Heterocyclic Compounds, 3-Ring/*adverse effects
MH  - Hospitals, Teaching
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/*epidemiology
MH  - Male
MH  - Middle Aged
MH  - Oxazines/*adverse effects
MH  - Piperazines/*adverse effects
MH  - Pyridones/*adverse effects
MH  - Tuberculosis/*epidemiology
MH  - Zambia/epidemiology
OTO - NOTNLM
OT  - HIV
OT  - Tuberculosis
OT  - dolutegravir
OT  - immune reconstitution inflammatory syndrome
EDAT- 2020/09/10 06:00
MHDA- 2021/06/04 06:00
CRDT- 2020/09/09 17:46
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/06/04 06:00 [medline]
PHST- 2020/09/09 17:46 [entrez]
AID - 10.1177/0049475520953704 [doi]
PST - ppublish
SO  - Trop Doct. 2021 Apr;51(2):216-218. doi: 10.1177/0049475520953704. Epub 2020 Sep 
      9.